Here are five things to know:
1. The brokers gave Mazor stock at 1.86 rating.
2. The seven brokers rate Mazor stock as “buy.”
3. There are three equities research analysts give the stock a “hold” and four with a “strong buy.”
4. The company’s rating score dropped 11.4 percent in 90 days.
5. The price target is $15.88, according to the brokers.
6. The brokers predict the company will post a $0.22 EPS for this quarter.
More articles on orthopedic devices:
Shoulder reconstruction device market to see rapid growth—With DePuy Synthes at the helm
New NuVasive CEO Gregory Lucier buys 34k shares—5 key notes
LESS Institute gets $30M senior credit facility—5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
